Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 13/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.35 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654236 | 1.00 | MIF (0.39) | MIFITGB3ITGA2BPDE3BPDE3A | |
| SCHEMBL5655145 | 0.90 | PDE3B (0.42) | MIFPDE3BPDE3A | |
| SCHEMBL5655143 | 0.90 | PDE3B (0.42) | MIFPDE3BPDE3A | |
| SCHEMBL5654137 | 0.89 | MIF (0.39) | MIFPDE3BPDE3A | |
| SCHEMBL5654140 | 0.89 | MIF (0.39) | MIFPDE3BPDE3A | |
| SCHEMBL5653151 | 0.87 | MIF (0.38) | MIFPDE3BPDE3A | |
| SCHEMBL6173311 | 0.87 | MIF (0.40) | MIFPDE3BPDE3A | |
| SCHEMBL5654369 | 0.87 | MIF (0.40) | MIFPDE3BPDE3A | |
| SCHEMBL5653159 | 0.87 | MIF (0.38) | MIFPDE3BPDE3A | |
| SCHEMBL5654604 | 0.85 | MIF (0.45) | MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281916-A1 | Substituted isoxazolines and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | disclosed |
| US-7081538-B1 | Substituted isoxazolines and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2006-07-25 | — | — | US | disclosed |
| EP-1242416-B1 | SUBSTITUTED ISOXAZOLINES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| EP-1242416-A1 | SUBSTITUTED ISOXAZOLINES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040222-A1 | SUBSTITUTED ISOXAZOLINES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281916-A1 | Substituted isoxazolines and their use as antibacterial agents | CYP2S1, CYP3A7, CYP3A5 | MIF 4704/4885ITGB3 3476/4885ITGA2B 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.